GENELUX CORP (GNLX) Stock Price & Overview
NASDAQ:GNLX • US36870H1032
Current stock price
The current stock price of GNLX is 2.56 USD. Today GNLX is down by -3.4%. In the past month the price increased by 3.23%. In the past year, price decreased by -11.11%.
GNLX Key Statistics
- Market Cap
- 114.714M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.87
- Dividend Yield
- N/A
GNLX Stock Performance
GNLX Stock Chart
GNLX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GNLX. When comparing the yearly performance of all stocks, GNLX is a bad performer in the overall market: 81.13% of all stocks are doing better.
GNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNLX. GNLX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNLX Earnings
On March 19, 2026 GNLX reported an EPS of -0.25 and a revenue of 8.00K. The company missed EPS expectations (-12.26% surprise).
GNLX Forecast & Estimates
12 analysts have analysed GNLX and the average price target is 17.85 USD. This implies a price increase of 597.27% is expected in the next year compared to the current price of 2.56.
GNLX Groups
Sector & Classification
GNLX Financial Highlights
Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 9.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.56% | ||
| ROE | -171.45% | ||
| Debt/Equity | 0 |
GNLX Ownership
GNLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 360.314B | ||
| AMGN | AMGEN INC | 15.1 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.53 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GNLX
Company Profile
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Company Info
IPO: 2023-01-26
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA US
Employees: 24
Phone: 13026365400
GENELUX CORP / GNLX FAQ
Can you describe the business of GENELUX CORP?
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Can you provide the latest stock price for GENELUX CORP?
The current stock price of GNLX is 2.56 USD. The price decreased by -3.4% in the last trading session.
Does GENELUX CORP pay dividends?
GNLX does not pay a dividend.
What is the ChartMill technical and fundamental rating of GNLX stock?
GNLX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for GENELUX CORP?
GENELUX CORP (GNLX) has a market capitalization of 114.71M USD. This makes GNLX a Micro Cap stock.
Can you provide the ownership details for GNLX stock?
You can find the ownership structure of GENELUX CORP (GNLX) on the Ownership tab.